AG
CDTX

Algert Global’s Cidara Therapeutics CDTX Stock Holding History

Algert Global’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-616
Closed -$21K – 371
2019
Q2 		$21K Buy
+616
New +$25.6K 0.01% 340

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Algert Global's CDTX Position: Q3 2019 in Review

Algert Global sold out of Cidara Therapeutics (CDTX) in Q3 2019, closing a stake of 616 shares — an estimated $21K sold.

Algert Global first reported a position in CDTX in Q2 2019 and held it in 1 quarter. The position peaked at $21K in Q2 2019. 39 funds tracked by Wall St. Rank hold CDTX as of Q3 2019.

  • Algert Global reported no remaining Cidara Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Algert Global sold 616 Cidara Therapeutics shares in Q3 2019, an estimated $21K.
  • Algert Global first reported a position in Cidara Therapeutics in Q2 2019 and held it in 1 quarter.
  • Algert Global's Cidara Therapeutics position peaked at $21K in Q2 2019.
  • 39 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2019.

Based on Algert Global's 13F filing for Q3 2019, filed 14 Nov 2019.